Arterial Hypertension and Exosomes and extracellular vesicles: what the trial registry contains
The ClinicalTrials.gov registry holds 8 records for exosomes in Arterial Hypertension: 2 recruiting now, 0 labelled Phase 3 or 4, across 5 countries. Snapshot 2026-08-29.
Why this is studied in Arterial Hypertension
Resistant hypertension is a plumbing-and-signalling problem: vascular stiffness, renal sodium handling and sympathetic tone. Cell approaches are studied mostly for endothelial repair and inflammation, usually as an add-on to drugs rather than a replacement. Blood pressure is also the most placebo-responsive vital sign in medicine, which shapes how these trials must be designed.
What exosomes means in this table
Exosome and extracellular-vesicle products are cell-free: vesicles harvested from cultured cells and given without the cells themselves. They are attractive commercially because they avoid live-cell logistics, and they are regulatorily contested for the same reason — several regulators have issued explicit warnings about unapproved exosome products marketed for human use.
The numbers
Every figure below comes from one reproducible query (hypertension x exosome) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 8 |
| Interventional studies in the sample | 2 |
| Recruiting right now | 2 |
| Completed | 6 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 or Phase 4 records | 0 |
| Countries with at least one site | 5 |
| Median planned enrolment | 73 participants |
| Largest single planned enrolment | 535 participants |
| First / most recent start year | 2016 — 2024 |
How mature is this evidence?
The evidence base is small and unfinished: 8 registered records with no later-phase work and 2 enrolling.
6 records are marked completed and 0 ended early (terminated, withdrawn or suspended): 0% of registrations did not run to plan.
| Phase label | Records | Share |
|---|---|---|
| Not applicable | 7 | 78% |
| Phase 1 | 1 | 11% |
| Phase 2 | 1 | 11% |
Median planned enrolment is 73 participants (largest single study: 535). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Country coverage runs to 5, but the distribution has a long tail behind United States at about 50% of mentions.
| Country | Studies with a site there |
|---|---|
| United States | 4 |
| France | 1 |
| Reunion | 1 |
| Switzerland | 1 |
| Indonesia | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
Sponsorship leans academic: 7 of the most frequent lead sponsors read as academic or hospital entities and 0 as companies. Who pays shapes what gets measured and what gets published.
- City of Hope Medical Center — 2 records
- Cairo University — 1 record
- University Hospital, Bordeaux — 1 record
- University of Alabama at Birmingham — 1 record
- Insel Gruppe AG, University Hospital Bern — 1 record
- Rockefeller University — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07183384 — MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction | Phase 1, Phase 2 | Recruiting | 80 | Universitas Padjadjaran | 2024-07-01 |
| NCT04154332 — Exosome Cargo From Preeclampsia Patients | n/a | Recruiting | 64 | University of Alabama at Birmingham | 2019-12-02 |
| NCT07224737 — Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma. | n/a | Completed | 230 | City of Hope Medical Center | 2024-06-21 |
| NCT07225452 — An Exosomal miRNA-based Liquid Biopsy for ICC Detection | n/a | Completed | 535 | City of Hope Medical Center | 2024-06-21 |
| NCT04142138 — When the Kidney Reacts to Nutritional Changes | n/a | Completed | 9 | Rockefeller University | 2020-02-22 |
| NCT03503461 — Major Activation Of NCC in Graft Urinary Exosomes | n/a | Completed | 67 | University Hospital, Bordeaux | 2018-06-21 |
| NCT03562715 — microRNAs Role in Pre-eclampsia Diagnosis | n/a | Completed | 200 | Cairo University | 2016-11-28 |
| NCT03034265 — New Biomarkers and Difficult-to-treat Hypertension | n/a | Completed | 24 | Insel Gruppe AG, University Hospital Bern | 2016-05 |
What this page does and does not tell you
None of these numbers say the therapy works. They say how much organised research exists and how far along it is; effect sizes live in published results, not registry entries.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many exosomes studies for Arterial Hypertension are recruiting right now?
2 of 8 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is exosomes an approved treatment for Arterial Hypertension?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 8 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on exosomes for Arterial Hypertension?
0 of 8 records carry a Phase 3 or Phase 4 label and 6 are marked completed. Registrations run from 2016 to 2024.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Arterial Hypertension: cell-therapy evidence and registered trials
- How much does stem cell therapy for Arterial Hypertension cost? (2026)
- Arterial Hypertension stem cell therapy — your questions answered (2026)
- Arterial Hypertension: cell-therapy evidence by therapy class
- MSC vs exosomes for Arterial Hypertension: what the registries show
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.